Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ee09dd9b260f28b2c62ac8039ab75332 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2019-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b011c6dd06600b8db5642d04444a877 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74d66f350a515a559cf4f0aac7c84414 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57333b24a778fcf76e1f136d1c8c585e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28b199ce02f6336843f24a26e25b80f1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9104b92a35e4528aa1e5ce55c7416bf3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_439b6d6ae3bff4798b33299b92bf9130 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4868fba3b101a0557b0ad073e676eb5a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da5a2fb5fa2fc27046c674d5a4ea5f13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e164c24a5824368405a55e190eb36f85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dc7a4590b5581e1101f43e7d036677a |
publicationDate |
2020-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2020071876-A1 |
titleOfInvention |
High concentration trastuzumab with reduced viscosity or antigen-binding fragment stabilizing agent thereof |
abstract |
The present invention relates to a stable pharmaceutical formulation comprising trastuzumab or an antigen-binding fragment thereof. |
priorityDate |
2018-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |